Latest Kalaris Therapeutics News & Updates

See the latest news and media coverage for Kalaris. We track all announcements, press releases, and industry mentions in real time, all in one place.

Kalaris Therapeutics (Kalaris)

Clinical-stage biopharmaceutical company developing retinal disease treatments

kalaristx.com

Company type: Private company
Number of employees: 2–25
Industry: Pharmaceuticals

Last updated Today

Latest news about Kalaris Therapeutics (Kalaris)

In short: Kalaris advanced its TH103 retinal treatment through clinical trials and secured $50 million in funding following a merger with AlloVir.

Company announcements

July 20 Kalaris

Kalaris appoints Liisa Bayko as Chief Financial Officer

She brings over 20 years of biotech finance experience and was previously a top-ranked analyst at Evercore ISI, supporting Kalaris' growth.

July 13 Kalaris

Kalaris reports positive TH103 Phase 1a SAD results from expanded AMD cohorts

Expanded data reinforced vision and retinal improvements, with extended treatment durability and no inflammation at the 2.5mg dose.

May 12 Kalaris

Kalaris reports Q1 2026 financial results and business updates

Net loss was $10.9 million, with $104.9 million cash; Phase 1b/2 study underway.

March 17 Kalaris

Kalaris reports 2025 financial results

Cash stands at $118M, funding operations to Q4 2027. Positive Phase 1a data for TH103 reported; Phase 1b/2 data expected 1H 2027. $50M private placement completed.

Media coverage

July 29 Stockhouse

AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina

(2024-11-08 | NDAQ:ALVR) AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina...

July 17 MarketWatch

Kalaris Therapeutics Shares Rise After More Positive Data From TH103 Trial

Kalaris Therapeutics shares rose on the back of news that the company had additional positive data from its Phase 1a single-ascending-dose trial of TH103 in...

June 23 Yahoo Finance

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Kalaris Therapeutics, Inc. (Nasdaq: KLRS) ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced an...

May 26 Newser

Kalaris Therapeutics Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights...

Kalaris (KLRS) earnings outlook | institutional accumulation, earnings catalysts, and market sentiment. Kalaris Therapeutics (KLRS) reported Q1 2026 earnings with a net loss of $0.46...

Never miss news about Kalaris

Track Kalaris and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Kalaris competitors & trending companies

Browse news for competitors to Kalaris and other trending companies.